Pfizer Inc. (NYSE:PFE) Shares Acquired by Tyche Wealth Partners LLC

Tyche Wealth Partners LLC lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 23.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,860 shares of the biopharmaceutical company’s stock after acquiring an additional 4,859 shares during the quarter. Tyche Wealth Partners LLC’s holdings in Pfizer were worth $686,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in the stock. Tectonic Advisors LLC grew its position in Pfizer by 23.5% in the fourth quarter. Tectonic Advisors LLC now owns 223,686 shares of the biopharmaceutical company’s stock worth $5,934,000 after buying an additional 42,570 shares during the last quarter. Money Concepts Capital Corp grew its position in Pfizer by 6.5% in the fourth quarter. Money Concepts Capital Corp now owns 208,071 shares of the biopharmaceutical company’s stock worth $5,520,000 after buying an additional 12,724 shares during the last quarter. Confluence Wealth Services Inc. grew its position in Pfizer by 6.0% in the fourth quarter. Confluence Wealth Services Inc. now owns 71,778 shares of the biopharmaceutical company’s stock worth $1,898,000 after buying an additional 4,084 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in Pfizer by 35.3% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,907,682 shares of the biopharmaceutical company’s stock worth $104,000,000 after purchasing an additional 1,019,400 shares during the period. Finally, Y.D. More Investments Ltd boosted its stake in Pfizer by 29.6% in the 4th quarter. Y.D. More Investments Ltd now owns 33,307 shares of the biopharmaceutical company’s stock worth $884,000 after purchasing an additional 7,602 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE:PFE opened at $26.46 on Thursday. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The stock has a market cap of $149.94 billion, a P/E ratio of 35.76, a price-to-earnings-growth ratio of 0.66 and a beta of 0.64. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The firm’s fifty day simple moving average is $26.27 and its 200 day simple moving average is $27.79.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. During the same quarter in the previous year, the firm earned $0.10 EPS. Pfizer’s revenue was up 24.7% on a year-over-year basis. As a group, research analysts predict that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.50%. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is presently 232.44%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on PFE shares. Guggenheim decreased their target price on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Citigroup dropped their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. UBS Group reduced their price target on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a research report on Wednesday, January 8th. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Finally, Sanford C. Bernstein started coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. One analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.